Development of Activated Carbon-Ceria Nanocomposite Materials for Prostate Cancer Therapy

Snima, K. S.; Sreelakshmi, K.; Renu, G.; Nair, Shantikumar V.; Subramanian, K. R. V.

doi:10.1166/asem.2013.1410

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is great concern for pharmaceutical industry to develop cost‐effective bulk production of different types of flavonoids [17] and nanotechnology field opened new avenue for low toxicity, increase bioavailability, and low cost to manage prostate‐related problems and various stages of prostate cancer [18]. As an example, studies clearly showed that biocompatible catechin‐loaded and gelatin‐conjugated carbon nanotubes have good anti‐cancer properties with the potential for targeting prostate PCa stem cells in combination with X‐ray irradiation [19] and multiwall carbon nanotubes [20], activated carbon‐ceria nanocomposite [21], proposed an attractive targeted drug delivery application for prostate cancer and therapy. Interestingly, an intralesional injection of gum arabic‐coated radioactive gold NPs were developed and resulted in minimal short‐term systemic toxicity in a naturally occurring large animal model of PCa [22].…”

Section: Introductionmentioning

confidence: 99%

Biophytum sensitivum nanomedicine reduces cell viability and nitrite production in prostate cancer cells

Raju

Nair

2017

IET nanobiotechnol.

Self Cite

View full text Add to dashboard Cite

Phytomedicine research received tremendous attention for novel therapeutic agent due to their safety and low cost. We assessed a novel nanoformulation of Biophytum sensitivum (BS), natural flavonoids for their improved efficacy and superior bioavailability against crude extract for prostate cancer cells (PC3). We prepared a nanomedicine of BS by nanoprecipitation method and size analysis via DLS and SEM revealed a range of 100-118 nm and surface zeta potential as −9.77 mV. FTIR was performed to evaluate functional for presence of carbonyl and aromatic rings, respectively. Human PC3 cells showed concentration at 0.5, 0.8, and 1 mg/ml dependent cytotoxicity 22, 39, and 56% for 24 h, whereas 43, 41, and 67% for 48 h of BS nanomedicine compared with crude 11, 22, and 53% for 24 h and 38, 31, and 60% for 48 h, respectively. Haemocompatibility of BS nanomedicine at the concentration of 0.5, 0.8, and 1 mg/ml did not show blood aggregation. Cellular uptake was confirmed using rhodamine-conjugated BS nanomedicine for 48 h. Interestingly, BS nanomedicine 1 mg/ml decreases the nitrite productions in PC3 cells. Collectively, BS nanomedicine has the potential anti-cancer agents with biocompatible and enhanced efficacy can be beneficial for the treatment of prostate cancer

show abstract